Immunoregulatory T Cells: Role and Potential as a Target in Malignancy

被引:19
作者
Beyer, Marc [1 ]
Schultze, Joachim L. [1 ]
机构
[1] Univ Cologne, Clin Internal Med 1, D-50931 Cologne, Germany
关键词
D O I
10.1007/s11912-008-0021-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Regulatory T cells (T-reg cells) are a highly specialized subset of immune cells capable of specifically suppressing autoreactive cells and thereby preventing autoimmunity. T-reg cells also play an important role in limiting the immune reaction in infectious diseases. In the context of malignancies, however, accumulation of T-reg cells occurs in the tumor microenvironment. T-reg cells have been associated with prevention of antitumor immunity and the evasion of efficient recognition of tumor antigens. In the past few years, several approaches have been developed to target and deplete T-reg cells in the context of tumors. Overall, these interventions have the potential to eliminate T-reg cells and thereby help strengthen antitumor immunity by vaccination.
引用
收藏
页码:130 / 136
页数:7
相关论文
共 50 条
[1]   Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production [J].
Allan, Sarah E. ;
Crome, Sarah Q. ;
Crellin, Natasha K. ;
Passerini, Laura ;
Steiner, Theodore S. ;
Bacchetta, Rosa ;
Roncarolo, Maria G. ;
Levings, Megan K. .
INTERNATIONAL IMMUNOLOGY, 2007, 19 (04) :345-354
[2]   Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2 [J].
Attia, P ;
Powell, DJ ;
Maker, AV ;
Kreitman, RJ ;
Pastan, I ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2006, 29 (02) :208-214
[3]   Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma [J].
Attia, P ;
Maker, AV ;
Haworth, LR ;
Rogers-Freezer, L ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :582-592
[4]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[5]  
BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69
[6]   Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine [J].
Beyer, M ;
Kochanek, M ;
Darabi, K ;
Popov, A ;
Jensen, M ;
Endl, E ;
Knolle, PA ;
Thomas, RK ;
von Bergwelt-Baildon, M ;
Bebey, S ;
Hallek, M ;
Schultze, JL .
BLOOD, 2005, 106 (06) :2018-2025
[7]   CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype [J].
Beyer, Marc ;
Schultze, Joachim L. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2628-2630
[8]   Regulatory T cells in cancer [J].
Beyer, Marc ;
Schultze, Joachim L. .
BLOOD, 2006, 108 (03) :804-811
[9]   In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma [J].
Beyer, Marc ;
Kochanek, Matthias ;
Giese, Thomas ;
Endl, Elmar ;
Weihrauch, Martin R. ;
Knolle, Percy A. ;
Classen, Sabine ;
Schultze, Joachim L. .
BLOOD, 2006, 107 (10) :3940-3949
[10]  
CHAKRABORTY NG, 1990, J IMMUNOL, V145, P2359